PHARMACOKINETICS AND IMMUNE RESPONSE STUDY WITH AN ANTI-CD3 MONOCLONAL ANTIBODY

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Monoclonal antibodies directed against the CD3 receptor of T lymphocytes (anti-CD3) have been shown to be effective immunosuppressive agents for use in clinical situations such as steroid-refractory allograft rejection following organ transplantation and diabetes. At the same time, administration of these monoclonal antibodies may be complicated by T-cell activation resulting in cytokine release syndrome (CRS). The purpose of this study is to investigate CNTO311, a genetically engineered anti-CD3 IgG monoclonal antibody, with regard to CRS. Favorable results will provide justification to develop CNTO311 for use in the clinical situations.